Related references
Note: Only part of the references are listed.The use of rapamycin to treat vascular tumours and malformations: A single-centre experience
Soumitra Tole et al.
PAEDIATRICS & CHILD HEALTH (2021)
Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation
Adelheid Wiemer-Kruel et al.
NEUROPEDIATRICS (2020)
Future treatments for hereditary hemorrhagic telangiectasia
Florian Robert et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Theranostic Advances in Vascular Malformations
Valerie Dekeuleneer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092)
Leslie G. Biesecker et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2020)
Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum
Victoria E. R. Parker et al.
GENETICS IN MEDICINE (2019)
Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review
Sameer D. Kini et al.
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY (2019)
Rapamycin and treatment of venous malformations
Emmanuel Seront et al.
CURRENT OPINION IN HEMATOLOGY (2019)
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Min Li et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Diagnosis and management of children with Blue Rubber Bleb Nevus Syndrome: A multi-center case series
Sara Isoldi et al.
DIGESTIVE AND LIVER DISEASE (2019)
Vascular Anomalies Diagnosis of Complicated Anomalies and New Medical Treatment Options
Denise M. Adams et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Alpelisib Treatment for Genital Vascular Malformation in a Patient with Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Spinal/Skeletal Anomalies and/or Scoliosis (CLOVES) Syndrome
Juan Carlos Lopez Gutierrez et al.
JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY (2019)
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor
Dong Li et al.
NATURE MEDICINE (2019)
Effect of sirolimus on coagulopathy of slow-flow vascular malformations
Joana M. Mack et al.
PEDIATRIC BLOOD & CANCER (2019)
m-TOR inhibitors and risk of Pneumocystis pneumonia after solid organ transplantation: a systematic review and meta-analysis
Maryam Ghadimi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors
Yuichi Ando et al.
CANCER SCIENCE (2019)
Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly
Lara Rodriguez-Laguna et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Genotype-Guided Medical Treatment of an Arteriovenous Malformation in a Child
Ramrada Lekwuttikarn et al.
JAMA DERMATOLOGY (2019)
Generalized Lymphatic Anomaly and Gorham-Stout Disease: Overview and Recent Insights
Michio Ozeki et al.
ADVANCES IN WOUND CARE (2019)
Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review
Ashleigh A. Halderman et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2018)
Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience
Darcy A. Krueger et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia
Joseph G. Parambil et al.
LARYNGOSCOPE (2018)
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
C. Ranieri et al.
NEUROGENETICS (2018)
Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
S. I. Nikolaev et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pneumocystis Jirovecii Pneumonia During Sirolimus Therapy for Kaposiform Hemangioendothelioma
Thomas B. Russell et al.
PEDIATRICS (2018)
A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas
Hanru Ying et al.
PEDIATRICS (2018)
Vascular Anomalies (Part I): Classification and Diagnostics of Vascular Anomalies
Maliha Sadick et al.
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN (2018)
Targeted therapy in patients with PIK3CA-related overgrowth syndrome
Quitterie Venot et al.
NATURE (2018)
Intranasal bevacizumab in the treatment of HHT - related epistaxis: a systematic review
P. Stokes et al.
RHINOLOGY (2018)
Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study
Jennifer Hammer et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
A Phase Ib Study of Alpelisib (BYL719), a PI3K alpha-Specific Inhibitor, with Letrozole in ER+/HER2(-) Metastatic Breast Cancer
Ingrid A. Mayer et al.
CLINICAL CANCER RESEARCH (2017)
Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies
Tomoyuki Mizuno et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations
Julie Soblet et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies
Tomoyuki Mizuno et al.
PEDIATRIC BLOOD & CANCER (2017)
High-dose calcineurin inhibitor-free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia
Yu-Ning Hu et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
Vascular Anomalies Caused by Abnormal Signaling within Endothelial Cells: Targets for Novel Therapies
Ha-Long Nguyen et al.
SEMINARS IN INTERVENTIONAL RADIOLOGY (2017)
Advances in the Medical Management of Vascular Anomalies
Kiersten W. Ricci
SEMINARS IN INTERVENTIONAL RADIOLOGY (2017)
Somatic MAP2K1 Mutations Are Associated with Extracranial Arteriovenous Malformation
Javier A. Couto et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2017)
Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review
Marion Nadal et al.
ACTA DERMATO-VENEREOLOGICA (2016)
GNA14 Somatic Mutation Causes Congenital and Sporadic Vascular Tumors by MAPK Activation
Young H. Lim et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2016)
Safety of mTOR inhibitors in adult solid organ transplantation
Pedro Ventura-Aguiar et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy
Hideki Matsumoto et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2016)
mTOR inhibitors effects on regulatory T cells and on dendritic cells
Giovanni Stallone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial
Iris E. Overwater et al.
NEUROLOGY (2016)
Response of Blue Rubber Bleb Nevus Syndrome to Sirolimus Treatment
Ralph Salloum et al.
PEDIATRIC BLOOD & CANCER (2016)
Tuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth
David Jenkins et al.
PEDIATRIC DERMATOLOGY (2016)
Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma
Vikash S. Oza et al.
PEDIATRIC DERMATOLOGY (2016)
Single-center experience with sirolimus therapy for vascular malformations
Sule Yesil et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2016)
Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies
Denise M. Adams et al.
PEDIATRICS (2016)
Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans
Sandra D. Castillo et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Characterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and Infants
C. Emoto et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2016)
Somatic Activating PIK3CA Mutations Cause Venous Malformation
Nisha Limaye et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2015)
Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms
Ionela Iacobas et al.
CLINICAL IMAGING (2015)
Sirolimus for the treatment of children with various complicated vascular anomalies
Herwig Lackner et al.
EUROPEAN JOURNAL OF PEDIATRICS (2015)
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study
Hilary J. Goldberg et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Common and specific effects of TIE2 mutations causing venous malformations
Marjut Natynki et al.
HUMAN MOLECULAR GENETICS (2015)
Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects
Elisa Boscolo et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma
Young H. Lim et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Successful Treatment of Kasabach-Merritt Phenomenon Arising From Kaposiform Hemangioendothelioma by Sirolimus
Zuopeng Wang et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2015)
Lymphatic and Other Vascular Malformative/Overgrowth Disorders Are Caused by Somatic Mutations in PIK3CA
Valerie L. Luks et al.
JOURNAL OF PEDIATRICS (2015)
Sirolimus for the Treatment of a Massive Capillary-Lymphatico-Venous Malformation: A Case Report
Aleksandar M. Vlahovic et al.
PEDIATRICS (2015)
Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies
Michel Wassef et al.
PEDIATRICS (2015)
Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome
Marjorie J. Lindhurst et al.
SCIENTIFIC REPORTS (2015)
Successful Treatment of Kaposiform Hemangioendothelioma With Everolimus
Teruaki Uno et al.
PEDIATRIC BLOOD & CANCER (2015)
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Mitsugu Shimobayashi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Treatment of a Tongue Lymphangioma With Sirolimus after Failure of Surgical Resection and Propranolol
Canan Akyuz et al.
PEDIATRIC BLOOD & CANCER (2014)
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
Kelvin Teck-Hong Kuik et al.
MEDICAL MYCOLOGY CASE REPORTS (2014)
A Case of Pneumocystis Pneumonia Associated with Everolimus Therapy for Renal Cell Carcinoma
Yoshinobu Saito et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Sturge-Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ
Matthew D. Shirley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1
Jeffrey R. Scott et al.
THERAPEUTIC DRUG MONITORING (2013)
Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
Sophie Dupuis-Girod et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Stewart-Treves syndrome: Pathogenesis and management
Amit Sharma et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Sirolimus for the Treatment of Complicated Vascular Anomalies in Children
Adrienne M. Hammill et al.
PEDIATRIC BLOOD & CANCER (2011)
Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case-control study
N. De Castro et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects
Vinciane Wouters et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient
Nikolina Basic-Jukic et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations
Nisha Limaye et al.
NATURE GENETICS (2009)
Use of sirolimus in solid organ transplantation
Joshua J. Augustine et al.
DRUGS (2007)
Mutation of the PIK3CA oncogene in human cancers
B Karakas et al.
BRITISH JOURNAL OF CANCER (2006)
Vascular malformations: localized defects in vascular morphogenesis
P Brouillard et al.
CLINICAL GENETICS (2003)
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
AS MacDonald
TRANSPLANTATION (2001)
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity
BD Kahan et al.
CLINICAL TRANSPLANTATION (2000)
Share Paper
